Background: Tissue-based assessment of actionable mutations in pts with NSCLC is limited by invasive biopsies and adequacy of biopsied tumour material. Blood-based testing may overcome such limitations, allowing multiplex profiling in a single test. BFAST (NCT03178552) is an ongoing multicentre, open-label, multi-cohort study evaluating the relationship between blood-based next-generation sequencing (NGS) detection of actionable genetic alterations in cell-free DNA, and the activity of targeted therapies and immunotherapy in pts with treatment-naïve advanced NSCLC. We present first results from the ALK+ cohort. Conclusions: Blood-based detection of ALK fusions results in high ORR and clinical benefit in pts receiving alectinib. These data validate the clinical utility of blood-based NGS as an additional method to inform clinical decision-making in ALK+ NSCLC. READ ARTICLE
Annals of Oncology DOI:10.1093/annonc/mdz394.079
Authors: S. M. Gadgeel, T. S. K. Mok, S. Peters, J. A. A. Alexander, N. B. Leighl, V. Sriuranpong, M. Perol, G. De Castro Jr., E. Nadal, F. De Marinis, J.-Y. Han, M. Yan, T. Riehl, E. Schleifman, S. M. Paul, S. Mocci, D. Shames, M. S. Mathisen, R. Dziadziuszko